Twenty-four-month results from a Pan-Asian real-world study show that Dienogest (Visanne) 2 mg effectively reduced endometriosis-associated pelvic pain (EAPP) and improved health-related quality of life (HRQoL) in Asian women with endometriosis. The important findings are from the ENVISIOeN(EffectiveNess of VISanne in Improving quality of life in Asian wOmen with eNdometriosis) study which evaluates the long-term efficacy and safety of Dienogest (Visanne) in the treatment of endometriosis in Asian women in real world clinical practice. The study was conducted in 36 sitesacrosssixAsian countries namely South Korea, Thailand, the Philippines, Singapore, Malaysia, and Indonesia.
“The 24-month findings of the study are encouraging news for endometriosis sufferers in Asia, given that endometriosis, is a chronic and painful disease affecting 1 in 10 women during their reproductive years. Results from the ENVISIOeN study represent an important milestone in defining a promising first-line treatment option for the long-term management of endometriosis,” said Dr. Maria Jesusa Banal-Silao, associate professor, Department of Obstetrics and Gynecology, University of the Philippines College of Medicine, Philippine General Hospital.
The 24-month results of the ENVISIOeN study were presented for the first time during the 8th Asian Conference on Endometriosis, from August 28 to 30 2 in Pattaya, Thailand.